Immune Profiling Edge Atreca's Immune Repertoire Capture technology enables detailed mapping of patients' immune responses, creating opportunities to partner in biomarker-driven patient selection, assay development, and discovery collaborations that de-risk immuno-oncology programs.

Strategic Refocus The sale of assets to Immunome signals openness to monetizing non-core assets and pursuing partnerships to advance remaining platforms, offering a pathway for licensing or co-development of IRC and related capabilities.

ADC Collaboration Past licensing with Zymeworks to access ZymeLink ADC technology shows willingness to engage in technology licensing and platform-enabled collaborations to accelerate antibody discovery and ADC programs.

Infectious Disease Potential Historically engaged in malaria prevention programs with Gates MRI demonstrates flexibility to apply the IRC platform beyond oncology, presenting opportunities for infectious disease or travel-medicine partnerships.

Partnership Readiness A seasoned leadership team with translational oncology focus, together with a solid funding base, suggests strong potential for milestone-driven collaborations, sponsored research, or co-development agreements.